Related references
Note: Only part of the references are listed.Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer
Carine M. Abdelmalek et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?
Shalini et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer
Tony Froehlich et al.
CHEMMEDCHEM (2020)
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Viktoriya Ivasiv et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs
Mahmud Hasan et al.
MOLECULAR PHARMACOLOGY (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm
Anthony F. Palermo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Drug conjugates-an emerging approach to treat breast cancer
Mahmud Hasan et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
Recent advances (2015-2016) in anticancer hybrids
Nagaraju Kerru et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
Patrick M. Kelly et al.
MOLECULES (2017)
Hybrid Compounds as Multitarget Directed Anticancer Agents
Ertan Kucuksayan et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101
Thomas Mehrling et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
Update on melatonin receptors: IUPHAR Review 20
Ralf Jockers et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold
Niall O. Keely et al.
BIOMEDICINES (2016)
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids
Rodrigo Mendoza-Sanchez et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
Xia Zhang et al.
SCIENTIFIC REPORTS (2015)
MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential
Darius P. Zlotos et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Advances in the development of hybrid anticancer drugs
Sebastien Fortin et al.
EXPERT OPINION ON DRUG DISCOVERY (2013)
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity
Berkley E. Gryder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Targeting the Estrogen Receptor using Steroid-Therapeutic Drug Conjugates (Hybrids)
Kinh-Luan Dao et al.
BIOCONJUGATE CHEMISTRY (2012)
Design, Synthesis and Biochemical Evaluation of Estrogen Receptor Ligand Conjugates as Tumour Targeting Agents
Niall O. Keely et al.
Letters in Drug Design & Discovery (2012)
Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries
Michael E. Jones et al.
BREAST CANCER RESEARCH (2012)
Clinical Phase II Study of Vorinostat, a Hydroxamic Type Histone Deacetylase Inhibitor, in Combination with Tamoxifen To Reverse Acquired Hormone Resistance in Breast Cancer Patients Who Progressed on Hormone Therapy.
P. Munster et al.
CANCER RESEARCH (2010)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Targeting Tumors Using Estrogen Receptor Ligand Conjugates
N. O. Keely et al.
CURRENT CANCER DRUG TARGETS (2009)
Estrogen receptors as therapeutic targets in breast cancer
Eric A. Ariazi et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
Designed multiple ligands. An emerging drug discovery paradigm
R Morphy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Diversity in the mechanisms of gene regulation by estrogen receptors
R Sanchez et al.
BIOESSAYS (2002)
The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators
AL Wijayaratne et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
